Clinical performance and decision thresholds of an automated plasma p-tau217 assay for amyloid pathology in a Taiwanese memory clinic

Background

Fully automated plasma p-tau217 assays may facilitate clinical implementation of blood-based testing for Alzheimer's disease (AD) amyloid pathology. However, data on assay-specific decision thresholds and clinical utility in East Asian memory-clinic populations remain limited.